{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:23:06Z","timestamp":1792272186936,"version":"4.4.0"},"reference-count":299,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T00:00:00Z","timestamp":1612483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Polskie Towarzystwo Chorob Metabolicznych","award":["Year 2020"],"award-info":[{"award-number":["Year 2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Metformin, one of the oldest oral antidiabetic agents and still recommended by almost all current guidelines as the first-line treatment for type 2 diabetes mellitus (T2DM), has become the medication with steadily increasing potential therapeutic indications. A broad spectrum of experimental and clinical studies showed that metformin has a pleiotropic activity and favorable effect in different pathological conditions, including prediabetes, type 1 diabetes mellitus (T1DM) and gestational diabetes mellitus (GDM). Moreover, there are numerous studies, meta-analyses and population studies indicating that metformin is safe and well tolerated and may be associated with cardioprotective and nephroprotective effect. Recently, it has also been reported in some studies, but not all, that metformin, besides improvement of glucose homeostasis, may possibly reduce the risk of cancer development, inhibit the incidence of neurodegenerative disease and prolong the lifespan. This paper presents some arguments supporting the initiation of metformin in patients with newly diagnosed T2DM, especially those without cardiovascular risk factors or without established cardiovascular disease or advanced kidney insufficiency at the time of new guidelines favoring new drugs with pleotropic effects complimentary to glucose control. Moreover, it focuses on the potential beneficial effects of metformin in patients with T2DM and coexisting chronic diseases.<\/jats:p>","DOI":"10.3390\/ph14020122","type":"journal-article","created":{"date-parts":[[2021,2,5]],"date-time":"2021-02-05T03:34:02Z","timestamp":1612496042000},"page":"122","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["The Current and Potential Therapeutic Use of Metformin\u2014The Good Old Drug"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6437-9476","authenticated-orcid":false,"given":"J\u00f3zef","family":"Drzewoski","sequence":"first","affiliation":[{"name":"Central Teaching Hospital of Medical University of Lodz, 92-213 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markolf","family":"Hanefeld","sequence":"additional","affiliation":[{"name":"Medical Clinic III, Department of Medicine Technical University Dresden, 01307 Dresden, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998). Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). Lancet, 352, 854\u2013865.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1001\/archinternmed.2010.409","article-title":"Metformin Use and Mortality among Patients with Diabetes and Atherothrombosis","volume":"170","author":"Roussel","year":"2010","journal-title":"Arch. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of Metformin versus Glipizide on Cardiovascular Outcomes in Patients with Type 2 Diabetes and Coronary Artery Disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Solym\u00e1r, M., Ivic, I., P\u00f3t\u00f3, L., Hegyi, P., Garami, A., Hartmann, P., P\u00e9terv\u00e1ri, E., Czopf, L., Hussain, A., and Gy\u00f6ngyi, Z. (2018). Metformin Induces Significant Reduction of Body Weight, Total Cholesterol and LDL Levels in the Elderly\u2014A Meta-Analysis. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207947"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12933-019-0900-7","article-title":"Effect of Metformin on All-Cause and Cardiovascular Mortality in Patients with Coronary Artery Diseases: A Systematic Review and an Updated Meta-Analysis","volume":"18","author":"Han","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-020-01100-w","article-title":"Metformin Treatment in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Regression Analysis","volume":"19","author":"Halabi","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1001\/archinte.168.19.2070","article-title":"Cardiovascular Outcomes in Trials of Oral Diabetes Medications: A Systematic Review","volume":"168","author":"Selvin","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1007\/s00125-017-4337-9","article-title":"Impact of Metformin on Cardiovascular Disease: A Meta-Analysis of Randomised Trials among People with Type 2 Diabetes","volume":"60","author":"Griffin","year":"2017","journal-title":"Diabetologia"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Boussageon, R., Supper, I., Bejan-Angoulvant, T., Kellou, N., Cucherat, M., Boissel, J.-P., Kassai, B., Moreau, A., Gueyffier, F., and Cornu, C. (2012). Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials. PLoS Med., 9.","DOI":"10.1371\/journal.pmed.1001204"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of Metformin on Cardiovascular Events and Mortality: A Meta-Analysis of Randomized Clinical Trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1007\/s00125-006-0316-2","article-title":"European Association for the Study of Diabetes Management of Hyperglycaemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A Consensus Statement from the American Diabetes Association and the European Association for the Study of Diabetes","volume":"49","author":"Nathan","year":"2006","journal-title":"Diabetologia"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"American Diabetes Association 9 (2020). Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2020. Diabetes Care, 43, S98\u2013S110.","DOI":"10.2337\/dc20-S009"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e3124","DOI":"10.1002\/dmrr.3124","article-title":"Cardiovascular Effects of SGLT-2 Inhibitors: What We Have Learned from Cardiovascular Outcome Trials and What We Still Need to Understand","volume":"35","author":"Cavallari","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s10557-018-6773-2","article-title":"GLP-1 Receptor Agonists and Cardiovascular Disease: A Meta-Analysis of Recent Cardiac Outcome Trials","volume":"32","author":"Jia","year":"2018","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1161\/CIRCRESAHA.117.311588","article-title":"Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors","volume":"122","author":"Scheen","year":"2018","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.31083\/j.rcm.2018.02.907","article-title":"Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review","volume":"19","author":"Kluger","year":"2018","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/dom.13698","article-title":"Duration of Diabetes and Cardiorenal Efficacy of Liraglutide and Semaglutide: A Post Hoc Analysis of the LEADER and SUSTAIN 6 Clinical Trials","volume":"21","author":"Verma","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.dsx.2019.04.028","article-title":"Should Metformin Still Be the First-Line of Treatment in Type 2 Diabetes Mellitus? A Comprehensive Review and Suggested Algorithm","volume":"13","author":"Abdelgadir","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/pdi.606","article-title":"Metformin: Its Botanical Background","volume":"21","author":"Bailey","year":"2004","journal-title":"Pract. Diabetes Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/pedi.12473","article-title":"Metformin; a Review of Its History and Future: From Lilac to Longevity","volume":"18","author":"Thomas","year":"2017","journal-title":"Pediatr. Diabetes"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0021-9258(18)86579-6","article-title":"Studies in the metabolism changes induced by administration of guanidine bases: I. Influence of injected guanidine hydrochloride upon blood sugar content","volume":"33","author":"Watanabe","year":"1918","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1039\/CT9222101790","article-title":"CCXIV.\u2014The Preparation of Methylguanidine, and of \u0392\u03b2-Dimethylguanidine by the Interaction of Dicyanodiamide, and Methylammonium and Dimethylammonium Chlorides Respectively","volume":"121","author":"Werner","year":"1922","journal-title":"J. Chem. Soc. Trans."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1042\/bj0170827","article-title":"The Constitution of Galegine","volume":"17","author":"Barger","year":"1923","journal-title":"Biochem. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D Deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/BF01862957","article-title":"Zur Pharmakologie des Galegins","volume":"125","author":"Reinwein","year":"1927","journal-title":"Naunyn-Schmiedebergs Arch. F\u00fcr Exp. Pathol. Pharmakol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lai, Y.-H., and Fang, T.-C. (2018, September 11). The Pleiotropic Effect of Vitamin D. Available online: https:\/\/www.hindawi.com\/journals\/isrn\/2013\/898125\/.","DOI":"10.5402\/2013\/898125"},{"key":"ref_30","first-page":"625","article-title":"[Treatment of diabetes mellitus with N,N-dimethylguanylguanidine (LA. 6023, glucophage)]","volume":"14","author":"Sterne","year":"1959","journal-title":"Therapie"},{"key":"ref_31","unstructured":"International Diabetes Federation (2021, January 22). Type 2 Diabetes. Available online: https:\/\/www.idf.org\/our-activities\/care-prevention\/type-2-diabetes.html."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","article-title":"Metformin Action: Concentrations Matter","volume":"21","author":"He","year":"2015","journal-title":"Cell Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s00508-016-1135-1","article-title":"Prescription of Oral Antidiabetic Drugs in Tyrol\u2014Data from the Tyrol Diabetes Registry 2012\u20132015","volume":"129","author":"Lunger","year":"2017","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_34","unstructured":"World Health Organization (2021, January 22). Model List of Essential Medicines. Available online: https:\/\/www.who.int\/publications-detail-redirect\/WHOMVPEMPIAU2019.06."},{"key":"ref_35","first-page":"2532","article-title":"Is Metformin a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics","volume":"23","author":"Huttunen","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrendo.2013.256","article-title":"Metformin\u2014Mode of Action and Clinical Implications for Diabetes and Cancer","volume":"10","author":"Pernicova","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10522-018-9773-5","article-title":"Metformin as a Geroprotector: Experimental and Clinical Evidence","volume":"20","author":"Piskovatska","year":"2019","journal-title":"Biogerontology"},{"key":"ref_38","first-page":"658","article-title":"Metformin: Current Knowledge","volume":"19","author":"Nasri","year":"2014","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The Mechanisms of Action of Metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1573399811666150325233108","article-title":"Molecular Action of Metformin in Hepatocytes: An Updated Insight","volume":"11","author":"Sliwinska","year":"2015","journal-title":"Curr. Diabetes Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1172\/JCI67227","article-title":"AMPK, Insulin Resistance, and the Metabolic Syndrome","volume":"123","author":"Ruderman","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00125-006-0141-7","article-title":"Effects of Metformin and Thiazolidinediones on Suppression of Hepatic Glucose Production and Stimulation of Glucose Uptake in Type 2 Diabetes: A Systematic Review","volume":"49","author":"Natali","year":"2006","journal-title":"Diabetologia"},{"key":"ref_43","first-page":"4059","article-title":"Metabolic Effects of Metformin on Glucose and Lactate Metabolism in Noninsulin-Dependent Diabetes Mellitus","volume":"81","author":"Cusi","year":"1996","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by Which Metformin Reduces Glucose Production in Type 2 Diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1056\/NEJM199803263381303","article-title":"Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus","volume":"338","author":"Inzucchi","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nrendo.2017.80","article-title":"Regulation of Hepatic Glucose Metabolism in Health and Disease","volume":"13","author":"Petersen","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E275","DOI":"10.1152\/ajpendo.2001.281.2.E275","article-title":"Mechanism of Fat-Induced Hepatic Gluconeogenesis: Effect of Metformin","volume":"281","author":"Song","year":"2001","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1056\/NEJM199508313330903","article-title":"Metabolic Effects of Metformin in Non-Insulin-Dependent Diabetes Mellitus","volume":"333","author":"Stumvoll","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.molmed.2008.09.007","article-title":"AMPK: A Metabolic Gauge Regulating Whole-Body Energy Homeostasis","volume":"14","author":"Lage","year":"2008","journal-title":"Trends Mol. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1113\/jphysiol.2006.113217","article-title":"AMPK Integrates Nutrient and Hormonal Signals to Regulate Food Intake and Energy Balance through Effects in the Hypothalamus and Peripheral Tissues","volume":"574","author":"Xue","year":"2006","journal-title":"J. Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1172\/JCI40671","article-title":"Metformin Inhibits Hepatic Gluconeogenesis in Mice Independently of the LKB1\/AMPK Pathway via a Decrease in Hepatic Energy State","volume":"120","author":"Foretz","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: From Mechanisms of Action to Therapies","volume":"20","author":"Foretz","year":"2014","journal-title":"Cell Metab."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"R97","DOI":"10.1530\/JOE-15-0447","article-title":"Current Understanding of Metformin Effect on the Control of Hyperglycemia in Diabetes","volume":"228","author":"An","year":"2016","journal-title":"J. Endocrinol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI13505","article-title":"Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action","volume":"108","author":"Zhou","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1126\/science.1120781","article-title":"The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin","volume":"310","author":"Shaw","year":"2005","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence That Metformin Exerts Its Anti-Diabetic Effects through Inhibition of Complex 1 of the Mitochondrial Respiratory Chain","volume":"348","author":"Owen","year":"2000","journal-title":"Biochem. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1074\/jbc.275.1.223","article-title":"Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I","volume":"275","author":"Nogueira","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3389\/fendo.2018.00753","article-title":"Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences","volume":"9","author":"Fontaine","year":"2018","journal-title":"Front. Endocrinol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/jcmm.13432","article-title":"Inhibition of Mitochondrial Complex I Improves Glucose Metabolism Independently of AMPK Activation","volume":"22","author":"Hou","year":"2018","journal-title":"J. Cell. Mol. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1021\/bi501473h","article-title":"Selective Inhibition of Deactivated Mitochondrial Complex I by Biguanides","volume":"54","author":"Matsuzaki","year":"2015","journal-title":"Biochemistry"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1113\/jphysiol.2006.108506","article-title":"Activation of AMP-Activated Protein Kinase in the Liver: A New Strategy for the Management of Metabolic Hepatic Disorders","volume":"574","author":"Viollet","year":"2006","journal-title":"J. Physiol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Kulkarni, A.S., Brutsaert, E.F., Anghel, V., Zhang, K., Bloomgarden, N., Pollak, M., Mar, J.C., Hawkins, M., Crandall, J.P., and Barzilai, N. (2018). Metformin Regulates Metabolic and Nonmetabolic Pathways in Skeletal Muscle and Subcutaneous Adipose Tissues of Older Adults. Aging Cell, 17.","DOI":"10.1111\/acel.12723"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.2337\/diabetes.51.7.2074","article-title":"Metformin Increases AMP-Activated Protein Kinase Activity in Skeletal Muscle of Subjects with Type 2 Diabetes","volume":"51","author":"Musi","year":"2002","journal-title":"Diabetes"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E1099","DOI":"10.1152\/ajpendo.00417.2013","article-title":"Two Weeks of Metformin Treatment Induces AMPK-Dependent Enhancement of Insulin-Stimulated Glucose Uptake in Mouse Soleus Muscle","volume":"306","author":"Kristensen","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"47898","DOI":"10.1074\/jbc.M408149200","article-title":"AMP-Activated Protein Kinase Is Required for the Lipid-Lowering Effect of Metformin in Insulin-Resistant Human HepG2 Cells","volume":"279","author":"Zang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cmet.2006.05.005","article-title":"Identification and Characterization of a Small Molecule AMPK Activator That Treats Key Components of Type 2 Diabetes and the Metabolic Syndrome","volume":"3","author":"Cool","year":"2006","journal-title":"Cell Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00125-009-1639-6","article-title":"Biguanides and Thiazolidinediones Inhibit Stimulated Lipolysis in Human Adipocytes through Activation of AMP-Activated Protein Kinase","volume":"53","author":"Bourron","year":"2010","journal-title":"Diabetologia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1074\/jbc.M114.567271","article-title":"Low Concentrations of Metformin Suppress Glucose Production in Hepatocytes through AMP-Activated Protein Kinase (AMPK)","volume":"289","author":"Cao","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cmet.2014.06.014","article-title":"The Lysosomal V-ATPase-Ragulator Complex Is a Common Activator for AMPK and MTORC1, Acting as a Switch between Catabolism and Anabolism","volume":"20","author":"Zhang","year":"2014","journal-title":"Cell Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nature11808","article-title":"Biguanides Suppress Hepatic Glucagon Signalling by Decreasing Production of Cyclic AMP","volume":"494","author":"Miller","year":"2013","journal-title":"Nature"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","article-title":"Metformin and the Gastrointestinal Tract","volume":"59","author":"McCreight","year":"2016","journal-title":"Diabetologia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1007\/s00125-008-1053-5","article-title":"Metformin and the Intestine","volume":"51","author":"Bailey","year":"2008","journal-title":"Diabetologia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jdi.12864","article-title":"Mechanisms of Metformin Action: In and out of the Gut","volume":"9","author":"Minamii","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: Clinical Use in Type 2 Diabetes","volume":"60","author":"Inzucchi","year":"2017","journal-title":"Diabetologia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.12854","article-title":"Understanding and Overcoming Metformin Gastrointestinal Intolerance","volume":"19","author":"Bonnet","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MCO.0000000000000468","article-title":"Metformin: Old Friend, New Ways of Action-Implication of the Gut Microbiome?","volume":"21","author":"Rodriguez","year":"2018","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.diabres.2014.08.004","article-title":"Mechanism of Increase in Plasma Intact GLP-1 by Metformin in Type 2 Diabetes: Stimulation of GLP-1 Secretion or Reduction in Plasma DPP-4 Activity?","volume":"106","author":"Wu","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1111\/j.1464-5491.2012.03675.x","article-title":"Effects of Chronic Treatment with Metformin on Dipeptidyl Peptidase-4 Activity, Glucagon-like Peptide 1 and Ghrelin in Obese Patients with Type 2 Diabetes Mellitus","volume":"29","author":"Thondam","year":"2012","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00125-017-4352-x","article-title":"The Effects of Metformin on Gut Microbiota and the Immune System as Research Frontiers","volume":"60","author":"Pollak","year":"2017","journal-title":"Diabetologia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nm.3787","article-title":"Metformin Activates a Duodenal Ampk-Dependent Pathway to Lower Hepatic Glucose Production in Rats","volume":"21","author":"Duca","year":"2015","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2165\/00003495-199958001-00009","article-title":"The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms","volume":"58","author":"Wiernsperger","year":"1999","journal-title":"Drugs"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mcna.2004.04.013","article-title":"Pathogenesis of Type 2 Diabetes Mellitus","volume":"88","author":"DeFronzo","year":"2004","journal-title":"Med. Clin. North. Am."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3G","DOI":"10.1016\/S0002-9149(02)02553-5","article-title":"Insulin Resistance as the Core Defect in Type 2 Diabetes Mellitus","volume":"90","author":"Goldstein","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1210\/jc.2002-021394","article-title":"Metformin Rapidly Increases Insulin Receptor Activation in Human Liver and Signals Preferentially through Insulin-Receptor Substrate-2","volume":"88","author":"Gunton","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00003495-199958001-00007","article-title":"Clinical Efficacy of Metformin against Insulin Resistance Parameters: Sinking the Iceberg","volume":"58","author":"Zimmet","year":"1999","journal-title":"Drugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6S28","DOI":"10.1016\/S1262-3636(03)72785-2","article-title":"Reducing Insulin Resistance with Metformin: The Evidence Today","volume":"29","author":"Giannarelli","year":"2003","journal-title":"Diabetes Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1210\/endo.131.3.1505458","article-title":"Cellular Mechanism of Metformin Action Involves Glucose Transporter Translocation from an Intracellular Pool to the Plasma Membrane in L6 Muscle Cells","volume":"131","author":"Hundal","year":"1992","journal-title":"Endocrinology"},{"key":"ref_88","first-page":"150","article-title":"Evidence That Metformin Ameliorates Cellular Insulin-Resistance by Potentiating Insulin-Induced Translocation of Glucose Transporters to the Plasma Membrane","volume":"17","author":"Matthaei","year":"1991","journal-title":"Diabete Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1210\/endo.133.1.8391425","article-title":"In Vivo Metformin Treatment Ameliorates Insulin Resistance: Evidence for Potentiation of Insulin-Induced Translocation and Increased Functional Activity of Glucose Transporters in Obese (Fa\/Fa) Zucker Rat Adipocytes","volume":"133","author":"Matthaei","year":"1993","journal-title":"Endocrinology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-319-48382-5_12","article-title":"Insulin Resistance, Obesity and Lipotoxicity","volume":"960","author":"Sezer","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1515\/JBCPP.1998.9.2-4.205","article-title":"Central Role of the Adipocyte in Insulin Resistance","volume":"9","author":"Bergman","year":"1998","journal-title":"J. Basic Clin. Physiol. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/978-3-319-48382-5_8","article-title":"What Is Lipotoxicity?","volume":"960","author":"Engin","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_93","first-page":"2186","article-title":"Neuro-Protective Role of Metformin in Patients with Acute Stroke and Type 2 Diabetes Mellitus via AMPK\/Mammalian Target of Rapamycin (MTOR) Signaling Pathway and Oxidative Stress","volume":"25","author":"Zhao","year":"2019","journal-title":"Med. Sci. Monit. Int. Med. J. Exp. Clin. Res."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhou, J., Massey, S., Story, D., and Li, L. (2018). Metformin: An Old Drug with New Applications. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102863"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdiacomp.2016.09.001","article-title":"Metformin Prevents Glucotoxicity by Alleviating Oxidative and ER Stress-Induced CD36 Expression in Pancreatic Beta Cells","volume":"31","author":"Moon","year":"2017","journal-title":"J. Diabetes Complicat."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7489795","DOI":"10.1155\/2020\/7489795","article-title":"Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications","volume":"2020","author":"Papachristoforou","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_97","first-page":"170","article-title":"Metformin\u2014Its Potential Anti-Cancer and Anti-Aging Effects","volume":"71","author":"Podhorecka","year":"2017","journal-title":"Postepy Hig. Med. Dosw. Online"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diabres.2018.05.023","article-title":"Metformin in Cancer","volume":"143","author":"Mallik","year":"2018","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/QAD.0b013e32834f33cc","article-title":"Effects of Lifestyle Modification and Metformin on Atherosclerotic Indices among HIV-Infected Patients with the Metabolic Syndrome","volume":"26","author":"Fitch","year":"2012","journal-title":"AIDS"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1756283X11403809","article-title":"The Role of Insulin-Sensitizing Agents in the Treatment of Nonalcoholic Steatohepatitis","volume":"4","author":"Rinella","year":"2011","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1517\/14656566.2014.944160","article-title":"What Are the Pharmacotherapy Options for Treating Prediabetes?","volume":"15","author":"Daniele","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_102","first-page":"2633494120908709","article-title":"What Is New in the Landscape of Insulin-Sensitizing Agents for Polycystic Ovary Syndrome Treatment","volume":"14","author":"Romualdi","year":"2020","journal-title":"Ther. Adv. Reprod. Health"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1517\/14656566.2014.855197","article-title":"The Latest Pharmacotherapy Options for Type 1 Diabetes","volume":"15","author":"Ludvigsson","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1007\/s00125-017-4364-6","article-title":"REMOVAL Study Team A New Perspective on Metformin Therapy in Type 1 Diabetes","volume":"60","author":"Livingstone","year":"2017","journal-title":"Diabetologia"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/1871530315666150316124019","article-title":"Metformin and Inflammation: Its Potential Beyond Glucose-Lowering Effect","volume":"15","author":"Saisho","year":"2015","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Kury\u0142owicz, A., and Ko\u017aniewski, K. (2020). Anti-Inflammatory Strategies Targeting Metaflammation in Type 2 Diabetes. Molecules, 25.","DOI":"10.3390\/molecules25092224"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2042018820926000","DOI":"10.1177\/2042018820926000","article-title":"Effects of Metformin in Obesity Treatment in Different Populations: A Meta-Analysis","volume":"11","author":"Pu","year":"2020","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"10975","DOI":"10.1038\/s41598-017-11430-7","article-title":"Metformin Improves Endothelial Function and Reduces Blood Pressure in Diabetic Spontaneously Hypertensive Rats Independent from Glycemia Control: Comparison to Vildagliptin","volume":"7","author":"Henning","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2710.1992.tb01271.x","article-title":"Metformin and Blood Pressure","volume":"17","year":"1992","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1160\/TH14-09-0797","article-title":"Metformin Reduces Hyper-Reactivity of Platelets from Patients with Polycystic Ovary Syndrome by Improving Mitochondrial Integrity","volume":"114","author":"Randriamboavonjy","year":"2015","journal-title":"Thromb. Haemost."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/annonc\/mdw410","article-title":"Metformin as an Adjuvant Treatment for Cancer: A Systematic Review and Meta-Analysis","volume":"27","author":"Coyle","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.tips.2018.07.006","article-title":"Metformin as an Anticancer Agent","volume":"39","author":"Vancura","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_113","first-page":"27","article-title":"Hypoglycemic Agents and Potential Anti-Inflammatory Activity","volume":"9","author":"Kothari","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1161\/CIRCULATIONAHA.110.014860","article-title":"Profibrinolytic, Antithrombotic, and Antiinflammatory Effects of an Insulin-Sensitizing Strategy in Patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial","volume":"124","author":"Sobel","year":"2011","journal-title":"Circulation"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.metabol.2012.06.009","article-title":"The Effect of Metformin on Monocyte Secretory Function in Simvastatin-Treated Patients with Impaired Fasting Glucose","volume":"62","author":"Krysiak","year":"2013","journal-title":"Metabolism"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.atherosclerosis.2012.09.034","article-title":"Lymphocyte-Suppressing and Systemic Anti-Inflammatory Effects of High-Dose Metformin in Simvastatin-Treated Patients with Impaired Fasting Glucose","volume":"225","author":"Krysiak","year":"2012","journal-title":"Atherosclerosis"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The Pathobiology of Diabetic Complications: A Unifying Mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0011-393X(02)80047-9","article-title":"Antioxidant Effects of Gliclazide, Glibenclamide, and Metformin in Patients with Type 2 Diabetes Mellitus","volume":"63","author":"Signorini","year":"2002","journal-title":"Curr. Ther. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clnu.2012.08.006","article-title":"Effects of Metformin on Markers of Oxidative Stress and Antioxidant Reserve in Patients with Newly Diagnosed Type 2 Diabetes: A Randomized Clinical Trial","volume":"32","author":"Esteghamati","year":"2013","journal-title":"Clin. Nutr."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Ara\u00fajo, A.A.D., Pereira, A.D.S.B.F., Medeiros, C.A.C.X.D., Brito, G.A.D.C., Leit\u00e3o, R.F.D.C., Ara\u00fajo, L.D.S., and Ara\u00fajo J\u00fanior, R.F.D. (2017). Effects of Metformin on Inflammation, Oxidative Stress, and Bone Loss in a Rat Model of Periodontitis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183506"},{"key":"ref_121","first-page":"40","article-title":"Metformin Attenuates ER Stress-Induced Mitochondrial Dysfunction","volume":"190","author":"Chen","year":"2017","journal-title":"Transl. Res. J. Lab. Clin. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.dsx.2015.08.016","article-title":"Anti Oxidant Potential of Metformin and Pioglitazone in Type 2 Diabetes Mellitus: Beyond Their Anti Glycemic Effect","volume":"10","author":"Singh","year":"2016","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_123","unstructured":"International Diabetes Federation (2019). Diabetes Atlas, International Diabetes Federation. [9th ed.]. Available online: https:\/\/www.diabetesatlas.org\/en\/."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1479164112451581","article-title":"Glucose Perturbations and Cardiovascular Risk: Challenges and Opportunities","volume":"9","author":"Mellbin","year":"2012","journal-title":"Diab. Vasc. Dis. Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1007\/s40265-015-0416-8","article-title":"Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention","volume":"75","author":"Hostalek","year":"2015","journal-title":"Drugs"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Diabetes Prevention Program Research Group Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.amepre.2018.04.038","article-title":"Review of Metformin Use for Type 2 Diabetes Prevention","volume":"55","author":"Moin","year":"2018","journal-title":"Am. J. Prev. Med."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"American Diabetes Association 3 (2020). Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes\u20142020. Diabetes Care, 43, S32\u2013S36.","DOI":"10.2337\/dc20-S003"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1210\/jc.2019-00129","article-title":"Metformin Improves Peripheral Insulin Sensitivity in Youth with Type 1 Diabetes","volume":"104","author":"Bergman","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2337\/diacare.26.1.138","article-title":"Metformin as an Adjunct Therapy in Adolescents with Type 1 Diabetes and Insulin Resistance: A Randomized Controlled Trial","volume":"26","author":"Hamilton","year":"2003","journal-title":"Diabetes Care"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0026-0495(85)90139-8","article-title":"Metformin Improved Insulin Resistance in Type I, Insulin-Dependent, Diabetic Patients","volume":"34","author":"Gin","year":"1985","journal-title":"Metabolism"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/pedi.12140","article-title":"Effects of Low Dose Metformin in Adolescents with Type I Diabetes Mellitus: A Randomized, Double-Blinded Placebo-Controlled Study","volume":"16","author":"Nadeau","year":"2015","journal-title":"Pediatr. Diabetes"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.2337\/diacare.25.12.2153","article-title":"The Benefits of Metformin Therapy during Continuous Subcutaneous Insulin Infusion Treatment of Type 1 Diabetic Patients","volume":"25","author":"Meyer","year":"2002","journal-title":"Diabetes Care"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Lund, S.S., Tarnow, L., Astrup, A.S., Hovind, P., Jacobsen, P.K., Alibegovic, A.C., Parving, I., Pietraszek, L., Frandsen, M., and Rossing, P. (2008). Effect of Adjunct Metformin Treatment in Patients with Type-1 Diabetes and Persistent Inadequate Glycaemic Control. A Randomized Study. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0003363"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00125-009-1636-9","article-title":"The Use of Metformin in Type 1 Diabetes: A Systematic Review of Efficacy","volume":"53","author":"Vella","year":"2010","journal-title":"Diabetologia"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1001\/jama.2015.16174","article-title":"Effect of Metformin Added to Insulin on Glycemic Control Among Overweight\/Obese Adolescents with Type 1 Diabetes: A Randomized Clinical Trial","volume":"314","author":"Libman","year":"2015","journal-title":"JAMA"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"DEPICT-1 Investigators Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.2337\/dci18-0041","article-title":"SGLT Inhibitors for Type 1 Diabetes: An Obvious Choice or Too Good to Be True?","volume":"41","author":"Riddle","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s12020-017-1264-y","article-title":"Euglycemic Ketosis in Patients with Type 2 Diabetes on SGLT2-Inhibitor Therapy-an Emerging Problem and Solutions Offered by Diabetes Technology","volume":"56","author":"Klonoff","year":"2017","journal-title":"Endocrine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium Glucose Cotransporter 2 Inhibitors and Risk of Serious Adverse Events: Nationwide Register Based Cohort Study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e000759","DOI":"10.1136\/bmjdrc-2019-000759","article-title":"Antidiabetic Medication Use during Pregnancy: An International Utilization Study","volume":"7","author":"Cesta","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.diabres.2014.10.001","article-title":"Metformin versus Insulin Treatment in Gestational Diabetes in Pregnancy in a Developing Country: A Randomized Control Trial","volume":"107","author":"Ainuddin","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1007\/s00125-017-4351-y","article-title":"Metformin Use in Pregnancy: Promises and Uncertainties","volume":"60","author":"Lindsay","year":"2017","journal-title":"Diabetologia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"325851","DOI":"10.1155\/2015\/325851","article-title":"Metformin Treatment in Type 2 Diabetes in Pregnancy: An Active Controlled, Parallel-Group, Randomized, Open Label Study in Patients with Type 2 Diabetes in Pregnancy","volume":"2015","author":"Ainuddin","year":"2015","journal-title":"J. Diabetes Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1056\/NEJMoa0707193","article-title":"MiG Trial Investigators Metformin versus Insulin for the Treatment of Gestational Diabetes","volume":"358","author":"Rowan","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e000456","DOI":"10.1136\/bmjdrc-2017-000456","article-title":"Metformin in Gestational Diabetes: The Offspring Follow-up (MiG TOFU): Body Composition and Metabolic Outcomes at 7\u20139 Years of Age","volume":"6","author":"Rowan","year":"2018","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"DEPICT-1 Investigators Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes (DEPICT-1): 24 Week Results from a Multicentre, Double-Blind, Phase 3, Randomised Controlled Trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients with Type 1 Diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1007\/s00125-017-4306-3","article-title":"Metformin Therapy for the Reproductive and Metabolic Consequences of Polycystic Ovary Syndrome","volume":"60","author":"Sam","year":"2017","journal-title":"Diabetologia"},{"key":"ref_152","first-page":"199","article-title":"The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis","volume":"128","author":"Zhao","year":"2020","journal-title":"Exp. Clin. Endocrinol. Diabetes Off. J. Ger. Soc. Endocrinol. Ger. Diabetes Assoc."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/humupd\/dmw025","article-title":"The Management of Anovulatory Infertility in Women with Polycystic Ovary Syndrome: An Analysis of the Evidence to Support the Development of Global WHO Guidance","volume":"22","author":"Balen","year":"2016","journal-title":"Hum. Reprod. Update"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e4526","DOI":"10.1097\/MD.0000000000004526","article-title":"Effects of Metformin on Pregnancy Outcomes in Women with Polycystic Ovary Syndrome: A Meta-Analysis","volume":"95","author":"Zeng","year":"2016","journal-title":"Medicine"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/er.2008-0030","article-title":"Evidence-Based and Potential Benefits of Metformin in the Polycystic Ovary Syndrome: A Comprehensive Review","volume":"30","author":"Palomba","year":"2009","journal-title":"Endocr. Rev."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e12964","DOI":"10.1111\/obr.12964","article-title":"Metformin in Pregnancy to Avert Gestational Diabetes in Women at High Risk: Meta-Analysis of Randomized Controlled Trials","volume":"21","author":"Doi","year":"2020","journal-title":"Obes. Rev. Off. J. Int. Assoc. Study Obes."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/aogs.13395","article-title":"Ovulation Induction in Polycystic Ovary Syndrome","volume":"97","author":"Tanbo","year":"2018","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.13968","article-title":"Effects of Empagliflozin on Metabolic Parameters in Polycystic Ovary Syndrome: A Randomized Controlled Study","volume":"90","author":"Javed","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/07435800.2014.966385","article-title":"Short-Term Intervention with Liraglutide Improved Eating Behavior in Obese Women with Polycystic Ovary Syndrome","volume":"40","author":"Jensterle","year":"2015","journal-title":"Endocr. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","article-title":"GLP-1 Receptor Agonists versus Metformin in PCOS: A Systematic Review and Meta-Analysis","volume":"39","author":"Han","year":"2019","journal-title":"Reprod. Biomed. Online"},{"key":"ref_161","first-page":"138","article-title":"Dipeptidyl Peptidase-4 and Adenosine Deaminase Enzyme Levels in Polycystic Ovary Syndrome","volume":"35","author":"Durak","year":"2019","journal-title":"Gynecol. Endocrinol. Off. J. Int. Soc. Gynecol. Endocrinol."},{"key":"ref_162","first-page":"69","article-title":"Dpp4 Inhibitor Sitagliptin as a Potential Treatment Option in Metformin-Intolerant Obese Women with Polycystic Ovary Syndrome: A Pilot Randomized Study","volume":"24","author":"Ferjan","year":"2018","journal-title":"Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/met.2017.0095","article-title":"Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Prevented Weight Regain in Obese Women with Polycystic Ovary Syndrome Previously Treated with Liraglutide: A Pilot Randomized Study","volume":"15","author":"Ferjan","year":"2017","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12944-018-0762-0","article-title":"Metformin Attenuates Triglyceride Accumulation in HepG2 Cells through Decreasing Stearyl-Coenzyme A Desaturase 1 Expression","volume":"17","author":"Zhu","year":"2018","journal-title":"Lipids Health Dis."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"E730","DOI":"10.1152\/ajpendo.00225.2016","article-title":"Treatment of Nonalcoholic Fatty Liver Disease: Role of AMPK","volume":"311","author":"Smith","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1507\/endocrj.EJ16-0295","article-title":"Amelioration of Fatty Liver Index in Patients with Type 2 Diabetes on Ipragliflozin: An Association with Glucose-Lowering Effects","volume":"64","author":"Takase","year":"2017","journal-title":"Endocr. J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk Factors for Coronary Artery Disease in Non-Insulin Dependent Diabetes Mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"DECODE Study Group, and European Diabetes Epidemiology Group (2003). Is the Current Definition for Diabetes Relevant to Mortality Risk from All Causes and Cardiovascular and Noncardiovascular Diseases?. Diabetes Care, 26, 688\u2013696.","DOI":"10.2337\/diacare.26.3.688"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(06)68967-8","article-title":"Relation between Age and Cardiovascular Disease in Men and Women with Diabetes Compared with Non-Diabetic People: A Population-Based Retrospective Cohort Study","volume":"368","author":"Booth","year":"2006","journal-title":"Lancet London England"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2796.2010.02265.x","article-title":"New Aspects of HbA1c as a Risk Factor for Cardiovascular Diseases in Type 2 Diabetes: An Observational Study from the Swedish National Diabetes Register (NDR)","volume":"268","author":"Cederholm","year":"2010","journal-title":"J. Intern. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.2337\/dc12-2412","article-title":"HbA1c and the Risks for All-Cause and Cardiovascular Mortality in the General Japanese Population: NIPPON DATA90","volume":"36","author":"Sakurai","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Hesen, N.A., Riksen, N.P., Aalders, B., Brouwer, M.A., Ritskes-Hoitinga, M., El Messaoudi, S., and Wever, K.E. (2017). A Systematic Review and Meta-Analysis of the Protective Effects of Metformin in Experimental Myocardial Infarction. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183664"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e3173","DOI":"10.1002\/dmrr.3173","article-title":"Mechanisms of Action of Metformin with Special Reference to Cardiovascular Protection","volume":"35","author":"Zilov","year":"2019","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20150497","article-title":"Repurposing Metformin: An Old Drug with New Tricks in Its Binding Pockets","volume":"471","author":"Pryor","year":"2015","journal-title":"Biochem. J."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.numecd.2017.04.009","article-title":"Metformin Effects on the Heart and the Cardiovascular System: A Review of Experimental and Clinical Data","volume":"27","author":"Nesti","year":"2017","journal-title":"Nutr. Metab. Cardiovasc. Dis. NMCD"},{"key":"ref_177","first-page":"225","article-title":"[Metformin and left ventricular remodeling after acute myocardial infarction: Molecular mechanisms and clinical implications]","volume":"16","author":"Paneni","year":"2015","journal-title":"G. Ital. Cardiol. 2006"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Dziubak, A., W\u00f3jcicka, G., Wojtak, A., and Be\u0142towski, J. (2018). Metabolic Effects of Metformin in the Failing Heart. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19102869"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1161\/CIRCRESAHA.108.190918","article-title":"Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure","volume":"104","author":"Gundewar","year":"2009","journal-title":"Circ. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2013.10.025","article-title":"Metformin and Liraglutide Ameliorate High Glucose-Induced Oxidative Stress via Inhibition of PKC-NAD(P)H Oxidase Pathway in Human Aortic Endothelial Cells","volume":"232","author":"Batchuluun","year":"2014","journal-title":"Atherosclerosis"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/14746514030030041501","article-title":"Metformin Inhibits Monocyte Adhesion to Endothelial Cells and Foam Cell Formation","volume":"3","author":"Mamputu","year":"2003","journal-title":"Br. J. Diabetes Vasc. Dis."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2018.02.017","article-title":"Metformin Ameliorates the Progression of Atherosclerosis via Suppressing Macrophage Infiltration and Inflammatory Responses in Rabbits","volume":"198","author":"Yang","year":"2018","journal-title":"Life Sci."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1365-2796.2004.01420.x","article-title":"Effects of Short-Term Treatment with Metformin on Markers of Endothelial Function and Inflammatory Activity in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Trial","volume":"257","author":"Kooy","year":"2005","journal-title":"J. Intern. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.bbrc.2017.03.036","article-title":"Metformin Improves Cardiac Function in Mice with Heart Failure after Myocardial Infarction by Regulating Mitochondrial Energy Metabolism","volume":"486","author":"Sun","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0168-8227(89)90058-2","article-title":"Study of the Effect of Metformin on Platelet Aggregation in Insulin-Dependent Diabetics","volume":"6","author":"Gin","year":"1989","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"H2123","DOI":"10.1152\/ajpheart.00707.2010","article-title":"Enhancing AMPK Activation during Ischemia Protects the Diabetic Heart against Reperfusion Injury","volume":"300","author":"Paiva","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2018.07.007","article-title":"Endothelial Function and Dysfunction: Impact of Metformin","volume":"192","author":"Nafisa","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.2337\/dc18-2356","article-title":"Effects of Metformin Therapy on Coronary Endothelial Dysfunction in Patients with Prediabetes with Stable Angina and Nonobstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study","volume":"42","author":"Sardu","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12933-019-0931-0","article-title":"Pericoronary Fat Inflammation and Major Adverse Cardiac Events (MACE) in Prediabetic Patients with Acute Myocardial Infarction: Effects of Metformin","volume":"18","author":"Sardu","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jacbts.2018.04.003","article-title":"Potentiation of Insulin Signaling Contributes to Heart Failure in Type 2 Diabetes: A Hypothesis Supported by Both Mechanistic Studies and Clinical Trials","volume":"3","author":"Packer","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1001\/archinternmed.2009.20","article-title":"Long-Term Effects of Metformin on Metabolism and Microvascular and Macrovascular Disease in Patients with Type 2 Diabetes Mellitus","volume":"169","author":"Kooy","year":"2009","journal-title":"Arch. Intern. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and Metabolic Effects of Metformin in Patients with Type 1 Diabetes (REMOVAL): A Double-Blind, Randomised, Placebo-Controlled Trial","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2004.01328.x","article-title":"The Effect of Metformin on Blood Pressure, Plasma Cholesterol and Triglycerides in Type 2 Diabetes Mellitus: A Systematic Review","volume":"256","author":"Kooy","year":"2004","journal-title":"J. Intern. Med."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Bassols, J., Mart\u00ednez-Calcerrada, J.-M., Osiniri, I., D\u00edaz-Rold\u00e1n, F., Xargay-Torrent, S., Mas-Par\u00e9s, B., Dorado-Ceballos, E., Prats-Puig, A., Carreras-Badosa, G., and de Zegher, F. (2019). Effects of Metformin Administration on Endocrine-Metabolic Parameters, Visceral Adiposity and Cardiovascular Risk Factors in Children with Obesity and Risk Markers for Metabolic Syndrome: A Pilot Study. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0226303"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/1475-2840-12-164","article-title":"Haemoglobin A1c Even within Non-Diabetic Level Is a Predictor of Cardiovascular Disease in a General Japanese Population: The Hisayama Study","volume":"12","author":"Ikeda","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/j.1464-5491.2008.02581.x","article-title":"Glycated Haemoglobin and Cardiovascular Outcomes in People with Type 2 Diabetes: A Large Prospective Cohort Study","volume":"25","author":"Elley","year":"2008","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s00125-005-1858-4","article-title":"HOPE investigators The Relationship between Dysglycaemia and Cardiovascular and Renal Risk in Diabetic and Non-Diabetic Participants in the HOPE Study: A Prospective Epidemiological Analysis","volume":"48","author":"Gerstein","year":"2005","journal-title":"Diabetologia"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.322.7277.15","article-title":"Glycated Haemoglobin, Diabetes, and Mortality in Men in Norfolk Cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk)","volume":"322","author":"Khaw","year":"2001","journal-title":"BMJ"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","article-title":"Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study","volume":"321","author":"Stratton","year":"2000","journal-title":"BMJ"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1056\/NEJM199508313330902","article-title":"Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus. The Multicenter Metformin Study Group","volume":"333","author":"DeFronzo","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"602","DOI":"10.7326\/0003-4819-154-9-201105030-00336","article-title":"Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations","volume":"154","author":"Bennett","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1743-7075-7-83","article-title":"Long-Term Effect of Metformin on Blood Glucose Control in Non-Obese Patients with Type 2 Diabetes Mellitus","volume":"7","author":"Ito","year":"2010","journal-title":"Nutr. Metab."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1001\/archinte.168.15.1699","article-title":"CHARM Program Investigators the Hemoglobin A1c Level as a Progressive Risk Factor for Cardiovascular Death, Hospitalization for Heart Failure, or Death in Patients with Chronic Heart Failure: An Analysis of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program","volume":"168","author":"Gerstein","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00125-007-0882-y","article-title":"HbA1c Measured in Stored Erythrocytes and Mortality Rate among Middle-Aged and Older Women","volume":"51","author":"Levitan","year":"2008","journal-title":"Diabetologia"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/0003-4819-141-6-200409210-00006","article-title":"Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk","volume":"141","author":"Khaw","year":"2004","journal-title":"Ann. Intern. Med."},{"key":"ref_206","first-page":"174","article-title":"Relationship of Hemoglobin A1c to Mortality in Nonsmoking Insurance Applicants","volume":"39","author":"Stout","year":"2007","journal-title":"J. Insur. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.2337\/diacare.28.10.2345","article-title":"Improved Clinical Outcomes Associated with Metformin in Patients with Diabetes and Heart Failure","volume":"28","author":"Eurich","year":"2005","journal-title":"Diabetes Care"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1093\/eurheartj\/ehz203","article-title":"A Randomized Controlled Trial of Metformin on Left Ventricular Hypertrophy in Patients with Coronary Artery Disease without Diabetes: The MET-REMODEL Trial","volume":"40","author":"Mohan","year":"2019","journal-title":"Eur. Heart J."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10557-013-6504-7","article-title":"Chronic Metformin Treatment Is Associated with Reduced Myocardial Infarct Size in Diabetic Patients with ST-Segment Elevation Myocardial Infarction","volume":"28","author":"Lexis","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1136\/bmj.39314.620174.80","article-title":"Benefits and Harms of Antidiabetic Agents in Patients with Diabetes and Heart Failure: Systematic Review","volume":"335","author":"Eurich","year":"2007","journal-title":"BMJ"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1161\/CIRCHEARTFAILURE.112.000162","article-title":"Comparative Safety and Effectiveness of Metformin in Patients with Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34,000 Patients","volume":"6","author":"Eurich","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7326\/M16-1901","article-title":"Clinical Outcomes of Metformin Use in Populations with Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review","volume":"166","author":"Crowley","year":"2017","journal-title":"Ann. Intern. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ijcard.2011.10.141","article-title":"Metformin Therapy and Prognosis of Patients with Heart Failure and New-Onset Diabetes Mellitus. A Propensity-Matched Study in the Community","volume":"166","author":"Romero","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"h4984","DOI":"10.1136\/bmj.h4984","article-title":"Association between Guideline Recommended Drugs and Death in Older Adults with Multiple Chronic Conditions: Population Based Cohort Study","volume":"351","author":"Tinetti","year":"2015","journal-title":"BMJ"},{"key":"ref_215","doi-asserted-by":"crossref","unstructured":"Al Ali, L., Hartman, M.T., Lexis, C.P.H., Hummel, Y.M., Lipsic, E., van Melle, J.P., van Veldhuisen, D.J., Voors, A.A., van der Horst, I.C.C., and van der Harst, P. (2016). The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0168340"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.kint.2018.04.011","article-title":"Analysis of the Global Burden of Disease Study Highlights the Global, Regional, and National Trends of Chronic Kidney Disease Epidemiology from 1990 to 2016","volume":"94","author":"Xie","year":"2018","journal-title":"Kidney Int."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol. CJASN"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/1753-0407.12969","article-title":"Review of Glucagon-like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in Patients with Chronic Kidney Disease and Their Renal Effects","volume":"11","author":"Sloan","year":"2019","journal-title":"J. Diabetes"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Garofalo, C., Borrelli, S., Liberti, M.E., Andreucci, M., Conte, G., Minutolo, R., Provenzano, M., and De Nicola, L. (2019). SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects. Med. Kaunas Lith., 55.","DOI":"10.3390\/medicina55060268"},{"key":"ref_223","first-page":"369","article-title":"Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther. Res. Treat. Educ. Diabetes Relat. Disord."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12933-019-0916-z","article-title":"Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes: A Network Meta-Analysis","volume":"18","author":"Fei","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.cbi.2011.03.014","article-title":"Metformin Attenuates Streptozotocin-Induced Diabetic Nephropathy in Rats through Modulation of Oxidative Stress Genes Expression","volume":"192","author":"Alhaider","year":"2011","journal-title":"Chem. Biol. Interact."},{"key":"ref_227","first-page":"621","article-title":"Ameliorative Effects of Metformin on Renal Histologic and Biochemical Alterations of Gentamicin-Induced Renal Toxicity in Wistar Rats","volume":"17","author":"Amini","year":"2012","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000481951","article-title":"Renoprotective Effects of Metformin","volume":"138","author":"Kajbaf","year":"2018","journal-title":"Nephron"},{"key":"ref_229","first-page":"423","article-title":"Bright Renoprotective Properties of Metformin: Beyond Blood Glucose Regulatory Effects","volume":"7","author":"Nasri","year":"2013","journal-title":"Iran. J. Kidney Dis."},{"key":"ref_230","doi-asserted-by":"crossref","unstructured":"Kawanami, D., Takashi, Y., and Tanabe, M. (2020). Significance of Metformin Use in Diabetic Kidney Disease. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124239"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.mce.2015.06.006","article-title":"Metformin Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction","volume":"412","author":"Cavaglieri","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s10916-019-1412-4","article-title":"Basic Research in Diabetic Nephropathy Health Care: A Study of the Renoprotective Mechanism of Metformin","volume":"43","author":"Xue","year":"2019","journal-title":"J. Med. Syst."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"F226","DOI":"10.1152\/ajprenal.00495.2014","article-title":"Activation of AMP-Activated Protein Kinase Inhibits ER Stress and Renal Fibrosis","volume":"308","author":"Kim","year":"2015","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/jcph.1452","article-title":"Association of Metformin Use with End-Stage Renal Disease in Patients with Type 2 Diabetes Mellitus: A Nationwide Cohort Study Under the Pay-for-Performance Program","volume":"59","author":"Lee","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2337\/dc19-0936","article-title":"The Long-Term Effects of Metformin on Patients with Type 2 Diabetic Kidney Disease","volume":"43","author":"Kwon","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1159\/000370034","article-title":"Metformin Use in Kidney Transplant Recipients in the United States: An Observational Study","volume":"40","author":"Stephen","year":"2014","journal-title":"Am. J. Nephrol."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Ekstr\u00f6m, N., Schi\u00f6ler, L., Svensson, A.-M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., and Gudbj\u00f6rnsdottir, S. (2012). Effectiveness and Safety of Metformin in 51 675 Patients with Type 2 Diabetes and Different Levels of Renal Function: A Cohort Study from the Swedish National Diabetes Register. BMJ Open, 2.","DOI":"10.1136\/bmjopen-2012-001076"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/dom.13642","article-title":"Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease","volume":"21","author":"Charytan","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_239","doi-asserted-by":"crossref","unstructured":"Bell, S., Farran, B., McGurnaghan, S., McCrimmon, R.J., Leese, G.P., Petrie, J.R., McKeigue, P., Sattar, N., Wild, S., and McKnight, J. (2017). Risk of Acute Kidney Injury and Survival in Patients Treated with Metformin: An Observational Cohort Study. BMC Nephrol., 18.","DOI":"10.1186\/s12882-017-0579-5"},{"key":"ref_240","first-page":"i1450","article-title":"Diabetes Treatments and Risk of Amputation, Blindness, Severe Kidney Failure, Hyperglycaemia, and Hypoglycaemia: Open Cohort Study in Primary Care","volume":"352","author":"Coupland","year":"2016","journal-title":"BMJ"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2478\/v10039-012-0017-7","article-title":"Inappropriate Metformin Prescribing in Elderly Type 2 Diabetes Mellitus (T2DM) Patients","volume":"57","author":"Kosmalski","year":"2012","journal-title":"Adv. Med. Sci."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A Nested Case-Control Analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Salpeter, S.R., Greyber, E., Pasternak, G.A., and Salpeter, E.E. (2010). Risk of Fatal and Nonfatal Lactic Acidosis with Metformin Use in Type 2 Diabetes Mellitus. Cochrane Database Syst. Rev., CD002967.","DOI":"10.1002\/14651858.CD002967.pub4"},{"key":"ref_244","first-page":"94","article-title":"Diabetes and Cancer: A Comprehensive Review","volume":"24","author":"Abudawood","year":"2019","journal-title":"J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.2337\/dc10-0666","article-title":"Diabetes and Cancer: A Consensus Report","volume":"33","author":"Giovannucci","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and Reduced Risk of Cancer in Diabetic Patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1021\/acs.molpharmaceut.5b00577","article-title":"Metformin: A Novel but Controversial Drug in Cancer Prevention and Treatment","volume":"12","author":"Sui","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"40767","DOI":"10.18632\/oncotarget.8194","article-title":"Repurposing Metformin for Cancer Treatment: Current Clinical Studies","volume":"7","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1158\/1078-0432.CCR-09-1805","article-title":"Metformin: A Therapeutic Opportunity in Breast Cancer","volume":"16","year":"2010","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00125-017-4372-6","article-title":"Repurposing Metformin for the Prevention of Cancer and Cancer Recurrence","volume":"60","author":"DeCensi","year":"2017","journal-title":"Diabetologia"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"4366","DOI":"10.1158\/0008-5472.CAN-10-1769","article-title":"Metformin, Independent of AMPK, Induces MTOR Inhibition and Cell-Cycle Arrest through REDD1","volume":"71","author":"Regazzetti","year":"2011","journal-title":"Cancer Res."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40880-017-0184-9","article-title":"Metformin Targets Multiple Signaling Pathways in Cancer","volume":"36","author":"Lei","year":"2017","journal-title":"Chin. J. Cancer"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/15384047.2014.987021","article-title":"AMPK\/MTOR-Mediated Inhibition of Survivin Partly Contributes to Metformin-Induced Apoptosis in Human Gastric Cancer Cell","volume":"16","author":"Han","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1530\/JME-19-0083","article-title":"The Role of an Anti-Diabetic Drug Metformin in the Treatment of Endocrine Tumors","volume":"63","author":"Thakur","year":"2019","journal-title":"J. Mol. Endocrinol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1158\/2159-8290.CD-12-0263","article-title":"Investigating Metformin for Cancer Prevention and Treatment: The End of the Beginning","volume":"2","author":"Pollak","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Griss, T., Vincent, E.E., Egnatchik, R., Chen, J., Ma, E.H., Faubert, B., Viollet, B., DeBerardinis, R.J., and Jones, R.G. (2015). Metformin Antagonizes Cancer Cell Proliferation by Suppressing Mitochondrial-Dependent Biosynthesis. PLoS Biol., 13.","DOI":"10.1371\/journal.pbio.1002309"},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Valaee, S., Yaghoobi, M.M., and Shamsara, M. (2017). Metformin Inhibits Gastric Cancer Cells Metastatic Traits through Suppression of Epithelial-Mesenchymal Transition in a Glucose-Independent Manner. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0174486"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.2337\/dc08-2175","article-title":"New Users of Metformin Are at Low Risk of Incident Cancer","volume":"32","author":"Libby","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/1940-6207.CAPR-10-0157","article-title":"Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-Analysis","volume":"3","author":"Decensi","year":"2010","journal-title":"Cancer Prev. Res."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2337\/dc09-1380","article-title":"Metformin Associated with Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16","volume":"33","author":"Landman","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"2834","DOI":"10.1111\/cas.14124","article-title":"Effects of Metformin and Phenformin on Apoptosis and Epithelial-Mesenchymal Transition in Chemoresistant Rectal Cancer","volume":"110","author":"Park","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/srep00362","article-title":"Metformin Kills and Radiosensitizes Cancer Cells and Preferentially Kills Cancer Stem Cells","volume":"2","author":"Song","year":"2012","journal-title":"Sci. Rep."},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1200\/JCO.2009.19.6410","article-title":"Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients with Breast Cancer","volume":"27","author":"Jiralerspong","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1158\/0008-5472.CAN-09-2994","article-title":"Metformin Selectively Targets Cancer Stem Cells, and Acts Together with Chemotherapy to Block Tumor Growth and Prolong Remission","volume":"69","author":"Hirsch","year":"2009","journal-title":"Cancer Res."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.2147\/CMAR.S174535","article-title":"Effects of Metformin Treatment on Radiotherapy Efficacy in Patients with Cancer and Diabetes: A Systematic Review and Meta-Analysis","volume":"10","author":"Rao","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"7676909","DOI":"10.1155\/2019\/7676909","article-title":"Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis","volume":"2019","author":"Mekuria","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1634\/theoncologist.2013-0111","article-title":"Metformin Is Associated with Survival Benefit in Cancer Patients with Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"18","author":"Yin","year":"2013","journal-title":"Oncologist"},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1093\/aje\/kwz157","article-title":"Metformin Treatment and Cancer Risk: Cox Regression Analysis, with Time-Dependent Covariates, of 320,000 Persons with Incident Diabetes Mellitus","volume":"188","author":"Dankner","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.cell.2013.02.035","article-title":"Metformin Retards Aging in C. Elegans by Altering Microbial Folate and Methionine Metabolism","volume":"153","author":"Cabreiro","year":"2013","journal-title":"Cell"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1038\/ncomms3192","article-title":"Metformin Improves Healthspan and Lifespan in Mice","volume":"4","author":"Mercken","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/dom.12354","article-title":"Can People with Type 2 Diabetes Live Longer than Those without? A Comparison of Mortality in People Initiated with Metformin or Sulphonylurea Monotherapy and Matched, Non-Diabetic Controls","volume":"16","author":"Bannister","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin Reduces All-Cause Mortality and Diseases of Ageing Independent of Its Effect on Diabetes Control: A Systematic Review and Meta-Analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_273","doi-asserted-by":"crossref","unstructured":"Chen, Y., Gong, X., Wang, L., and Guo, J. (2020). Effects of Hypertension, Diabetes and Coronary Heart Disease on COVID-19 Diseases Severity: A Systematic Review and Meta-Analysis. medRxiv.","DOI":"10.1101\/2020.03.25.20043133"},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1007\/s00508-020-01672-3","article-title":"Diabetes and COVID-19: Disease-Management-People","volume":"132","author":"Peric","year":"2020","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_275","doi-asserted-by":"crossref","unstructured":"Guan, W.-J., Liang, W.-H., Zhao, Y., Liang, H.-R., Chen, Z.-S., Li, Y.-M., Liu, X.-Q., Chen, R.-C., Tang, C.-L., and Wang, T. (2020). Comorbidity and Its Impact on 1590 Patients with COVID-19 in China: A Nationwide Analysis. Eur. Respir. J., 55.","DOI":"10.1183\/13993003.01227-2020"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S2213-8587(20)30152-2","article-title":"Practical Recommendations for the Management of Diabetes in Patients with COVID-19","volume":"8","author":"Bornstein","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_277","first-page":"E34","article-title":"Metformin and Risk of Mortality in Patients Hospitalised with COVID-19: A Retrospective Cohort Analysis","volume":"2","author":"Bramante","year":"2021","journal-title":"Alliance Pandemic Prep."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1464-5491.2007.02078.x","article-title":"Initial Monotherapy with Either Metformin or Sulphonylureas Often Fails to Achieve or Maintain Current Glycaemic Goals in Patients with Type 2 Diabetes in UK Primary Care","volume":"24","author":"Cook","year":"2007","journal-title":"Diabet. Med. J. Br. Diabet. Assoc."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s42000-019-00093-w","article-title":"Metformin and Gut Microbiota: Their Interactions and Their Impact on Diabetes","volume":"18","author":"Vallianou","year":"2019","journal-title":"Hormones"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40264-020-00955-y","article-title":"A New Drug-Drug Interaction Between Hydroxychloroquine and Metformin? A Signal Detection Study","volume":"43","author":"Montastruc","year":"2020","journal-title":"Drug Saf."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/clpt.2012.210","article-title":"The Effect of Novel Promoter Variants in MATE1 and MATE2 on the Pharmacokinetics and Pharmacodynamics of Metformin","volume":"93","author":"Stocker","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","article-title":"Effect of Genetic Variation in the Organic Cation Transporter 1 (OCT1) on Metformin Action","volume":"117","author":"Shu","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10038-006-0087-0","article-title":"Human Organic Cation Transporter (OCT1 and OCT2) Gene Polymorphisms and Therapeutic Effects of Metformin","volume":"52","author":"Shikata","year":"2007","journal-title":"J. Hum. Genet."},{"key":"ref_284","first-page":"242","article-title":"Genetic Variation in the Organic Cation Transporter 1 Is Associated with Metformin Response in Patients with Diabetes Mellitus","volume":"9","author":"Becker","year":"2009","journal-title":"Pharm. J."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin Pathways: Pharmacokinetics and Pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet. Genom."},{"key":"ref_286","doi-asserted-by":"crossref","unstructured":"Nasykhova, Y.A., Tonyan, Z.N., Mikhailova, A.A., Danilova, M.M., and Glotov, A.S. (2020). Pharmacogenetics of Type 2 Diabetes-Progress and Prospects. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186842"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s00125-017-4227-1","article-title":"Pharmacogenetics in Type 2 Diabetes: Precision Medicine or Discovery Tool?","volume":"60","author":"Florez","year":"2017","journal-title":"Diabetologia"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"e11349","DOI":"10.1097\/MD.0000000000011349","article-title":"Genetic Polymorphisms of Organic Cation Transporter 1 (OCT1) and Responses to Metformin Therapy in Individuals with Type 2 Diabetes: A Systematic Review","volume":"97","author":"Essop","year":"2018","journal-title":"Medicine"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.biocel.2013.06.022","article-title":"Multidrug and Toxin Extrusion Proteins (MATE\/SLC47); Role in Pharmacokinetics","volume":"45","author":"Staud","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/j.1476-5381.2012.01853.x","article-title":"Loss of Multidrug and Toxin Extrusion 1 (MATE1) Is Associated with Metformin-Induced Lactic Acidosis","volume":"166","author":"Toyama","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1124\/dmd.107.015495","article-title":"Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human Intestine","volume":"35","author":"Zhou","year":"2007","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/cpt.567","article-title":"Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis","volume":"101","author":"Dujic","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2337\/dc15-0542","article-title":"Potential Impact of Prescribing Metformin According to EGFR Rather Than Serum Creatinine","volume":"38","author":"Tuot","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_294","doi-asserted-by":"crossref","unstructured":"Fatima, M., Sadeeqa, S., and Nazir, S.U.R. (2018). Metformin and Its Gastrointestinal Problems: A Review. Biomed. Res., 29.","DOI":"10.4066\/biomedicalresearch.40-18-526"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"e17918","DOI":"10.1097\/MD.0000000000017918","article-title":"Association between Metformin Dose and Vitamin B12 Deficiency in Patients with Type 2 Diabetes","volume":"98","author":"Kim","year":"2019","journal-title":"Medicine"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2015-3754","article-title":"Long-Term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study","volume":"101","author":"Aroda","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4103\/0022-3859.123143","article-title":"Association of B12 Deficiency and Clinical Neuropathy with Metformin Use in Type 2 Diabetes Patients","volume":"59","author":"Singh","year":"2013","journal-title":"J. Postgrad. Med."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2337\/dc11-1582","article-title":"Association of Biochemical B12 Deficiency with Metformin Therapy and Vitamin B12 Supplements: The National Health and Nutrition Examination Survey, 1999\u20132006","volume":"35","author":"Reinstatler","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.2337\/dc20-1104","article-title":"Risk of Anemia with Metformin Use in Type 2 Diabetes: A MASTERMIND Study","volume":"43","author":"Donnelly","year":"2020","journal-title":"Diabetes Care"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/2\/122\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:20:28Z","timestamp":1760160028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/2\/122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,5]]},"references-count":299,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["ph14020122"],"URL":"https:\/\/doi.org\/10.3390\/ph14020122","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,5]]}}}